Company Overview and News
Here's your June 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains reports. Nano-Cap MoPays are not listed.
SCA CCAOF "NHF" CJ CBL WSR CRLFF AD ALARF CRIUF ORC MHIVF OXLCO OXLCN SCM ATGFF SOT.UN CJR.B ECC AMZA ECCZ AGNC AHOTF ECCY PHK SRRTF QYLD PSEC OXLC ECCB NCV CJREF SCQ ECCA SUNS GNL NCZ NHF GNL.PRA PBB SRT.UN
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
CCAOF EBGUF FFN OSP.PR.A CBL NAF.UN AD ALARF CRIUF BNEFF CHW.DB SOT.UN CJR.B CHW MR.UN AHOTF OSP CNDCF BK CHWWF CGIFF BNE LCS CJREF LCS.PR.A FNCSF
Here's your April 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Reports. Nano-Cap MoPays are not listed.
SCA CCAOF CBL GOOD AD ALARF ORC OXLCO OXLCN SCM GOODM RNW GOODN CJR.B ECC ECCZ AGNC AHOTF DR.DB.A ECCY GOODO GOODP TRSWF DR MFCSF PSEC OXLC ECCB SCQ CJREF ECCA GNL GNL.PRA PBB
NEW YORK/TORONTO (Reuters) - Shares of Callidus Capital Corp (CBL.TO), the Canadian lending company owned by private equity firm Catalyst Capital Group Inc, plunged to an all-time low on Tuesday after it reported a fourth-quarter and annual loss late on Monday.
CCAOF CBL NYTAB
TORONTO/NEW YORK (Reuters) - Shares of Canadian lender Callidus Capital Corp lost as much as 21.6 percent in two trading sessions, hitting an all-time low, after a Reuters report on Friday raised questions about the valuations that parent company Catalyst Capital Group Inc assigned to some of its portfolio companies.
Contents: 1. US/CDN Stocks @6.5%+ yield (125) 2. Stocks by price upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) @6.5%+ yield (70).
FNNCF CCAOF CBL AD CRIUF ALARF BNEFF ORC SOT.UN CJR.B ECC DGS.PR.A ECCZ AGNC AHOTF ECCY DGS DVSPF ECCB BNE CJREF ECCA GNL GNL.PRA
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET